#South Korea #Seoul #Korea University #Lecanemab #p-Tau217

Korea University Study on Alzheimer's Treatment Response

In a groundbreaking study, researchers from Korea University's College of Medicine have unveiled significant findings regarding the monitoring of treatment responses in early Alzheimer's disease (AD). Led by Associate Professor Sung Hoon Kang, the research focuses on the use of a blood biomarker known as plasma phosphorylated tau 217 (p-tau217) to evaluate the effects of lecanemab, an anti-amyloid therapy recently approved for early AD patients.

Alzheimer's Disease and Lecanemab

Alzheimer's disease is a complex neurodegenerative disorder marked by the accumulation of amyloid-beta plaques and tau tangles within the brain. Traditional diagnostic methods, such as PET imaging, can be invasive and costly. Lecanemab aims to address this issue by targeting amyloid-beta to slow disease progression. However, the variability in individual responses to treatment necessitates a reliable and accessible method to monitor these responses closely.

The Study’s Design and Findings

The prospective study followed 153 patients undergoing treatment with lecanemab. Researchers assessed plasma p-tau217 levels at baseline, as well as at three and six months into therapy. They also evaluated cognitive function through standardized tests, including the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating–Sum of Boxes (CDR-SB).

Interestingly, the study found that plasma p-tau217 levels dropped significantly starting three months after treatment commenced, with the most pronounced decline occurring between three and six months, after which the levels plateaued. This pattern reveals critical insights into the biomarker’s potential for guiding treatment decisions.

Distinct Response Patterns

Patients exhibited two distinct patterns in their p-tau217 response: those who experienced a more substantial reduction in levels displayed notably more favorable cognitive trajectories. Specifically, they showed a slower worsening of CDR-SB scores. Of the 153 patients, 81 provided complete p-tau217 measurements throughout the study, which facilitated the identification of these trends and response patterns.

Moreover, the study observed an interesting link between hypertension and biomarker response. Patients with baseline hypertension showcased a weaker response in p-tau217 levels, highlighting the importance of considering patient comorbidities when interpreting treatment responses.

Implications for Clinical Practice

Dr. Kang emphasized the potential utility of p-tau217 as a less invasive and more cost-effective biomarker for monitoring biological responses to lecanemab. Traditionally, monitoring has required frequent PET imaging, which can place a financial burden on both patients and healthcare systems. Repeated assessments of p-tau217 may thus allow clinicians to gain valuable insights into treatment efficacy with greater ease and accessibility.

The findings from this study pave the way for future research into the standardization of p-tau217 measurements in routine clinical settings. Establishing clinically meaningful thresholds will be essential to optimize treatment planning and improve patient outcomes.

Ultimately, as the landscape of Alzheimer's treatment continues to evolve, the integration of accessible biomarkers like p-tau217 may signify a pivotal shift in how healthcare providers monitor and personalize therapy for individuals with early Alzheimer's disease. Further multicenter studies are encouraged to validate these promising results and fully realize the potential of p-tau217 in clinical practice.